Last update 21 Jun 2024

Telmisartan

Last update 21 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid, 4'-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid, 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid

+ [68]

Target

AT1R

Mechanism

AT1R antagonists(Angiotensin II Receptor Type 1 antagonists)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Cardiovascular DiseasesEssential HypertensionHypertension

Inactive Indication

Diabetes Mellitus, Type 2Diabetic NephropathiesHypercholesterolemia+ [3]

Originator Organization

Boehringer Ingelheim GmbH

Active Organization

Boehringer Ingelheim International GmbHNippon Boehringer Ingelheim Co., Ltd.

KRKA dd

+ [7]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (10 Nov 1998),

Hypertension

RegulationPriority Review (CN)

Structure

Molecular FormulaC33H30N4O2

InChIKeyRMMXLENWKUUMAY-UHFFFAOYSA-N

CAS Registry144701-48-4

311

Clinical Trials associated with Telmisartan

NCT06168487 / Not yet recruitingEarly Phase 1IIT

Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer

The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer.

Start Date01 Jun 2024

Sponsor / Collaborator

Dartmouth-Hitchcock Medical Center

CTRI/2024/02/062737 / Not yet recruitingPhase 3

Comparing Telmisartan Administration Regimens for Stage 1 Hypertension Treatment Morning Bedtime and Split Dose Approaches - NIL

Start Date26 Feb 2024

Sponsor / Collaborator-

CTRI/2024/02/062389 / Not yet recruitingNot Applicable

Effectiveness and Safety of Amlodipine and Telmisartanin Treatment Naïve Hypertension: An EMR-basedRetrospective, Comparative Study - NIL

Start Date15 Feb 2024

Sponsor / Collaborator

Dr. Reddy's Laboratories Ltd.

100 Clinical Results associated with Telmisartan

100 Translational Medicine associated with Telmisartan

100 Patents (Medical) associated with Telmisartan

2,658

Literatures (Medical) associated with Telmisartan

01 May 2024·Current drug safety

Tizanidine Induced Hypotension: Report of a Case and Review of the Literature

Review

Author: Kalita, Jayantee ; Mahajan, Roopali

Introduction::

Spasticity is a common sequelae of stroke, and often these patients receive anti-spastic drugs such as baclofen or tizanidine. Stroke patients have multiple co-morbidities such as hypertension, diabetes, and seizure. Tizanidine is an α2 and imidazole receptor agonist at a spinal and supraspinal level resulting in reduced central sympathetic outflow and causing hypotension rarely, especially in those receiving beta-blockers or angiotensin-converting enzyme inhibitors.

Case Presentation::

We report a 56-year-old hypertensive male presenting with altered sensorium who had recurrent intracerebral hemorrhage with left spastic hemiplegia and focal seizures. He was on amlodipine, atenolol, telmisartan and oxcarbazepine. After 3 doses of tizanidine 2mg, his blood pressure dropped from 140/90 to 80/40 mmHg and pulse from 82 bpm to 44 bpm. His blood counts, serum chemistry, procalcitonin, and Trop I were normal. ECG revealed sinus bradycardia. After 8 hours of withdrawing tizanidine, his blood pressure became 110/70 mmHg, and on the next day, it became 140/82 mmHg. His attendants were taught physiotherapy to minimize spasticity.

Conclusion::

This patient highlights the need for close monitoring of patients receiving tizanidine co-medication with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. These drugs have a synergistic effect on reducing the renin-angiotensin-aldosterone system, thereby hypotension and bradycardia.

01 Mar 2024·Journal of ethnopharmacology

Ameliorative effects of Modified Huangqi Chifeng decoction on podocyte injury via autophagy mediated by PI3K/AKT/mTOR and AMPK/mTOR pathways

Article

Author: Zhang, Yu ; Yang, Bin ; Shi, Xiujie ; Yin, Yundong ; Li, Peng ; Ma, Sijia ; Chang, Meiying ; Li, Qi ; Zhao, Mingming

ETHNOPHARMACOLOGICAL RELEVANCE:

Proteinuria is recognized as a risk factor for the exacerbation of chronic kidney disease. Modified Huangqi Chifeng decoction (MHCD) has distinct advantages in reducing proteinuria. Our previous experimental results have shown that MHCD can inhibit excessive autophagy. However, the specific mechanism by which MHCD regulates autophagy needs to be further explored.

AIM OF THE STUDY:

In this study, in vivo and in vitro experiments were conducted to further clarify the protective mechanism of MHCD on the kidney and podocytes by regulating autophagy based on phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and adenosine monophosphate-activated protein kinase (AMPK)/mTOR signaling pathways.

MATERIALS AND METHODS:

By a single injection via the tail vein, Sprague-Dawley rats received Adriamycin (5 mg/kg) to establish a model of proteinuria nephropathy. They were divided into control, model, MHCD, 3-methyladenine (3 MA), 3 MA + MHCD, and telmisartan groups and were administered continuously for 6 weeks. The MHCD-containing serum was prepared, and a model of podocyte injury induced by Adriamycin (0.2 μg/mL) was established.

RESULTS:

MHCD reduced the 24-h urine protein levels and relieved pathological kidney damage. During autophagy in the kidneys of rats with Adriamycin-induced nephropathy, the PI3K/AKT/mTOR signaling pathway is inhibited, while the AMPK/mTOR signaling pathway is activated. MHCD antagonized these effects, thereby inhibiting excessive autophagy. MHCD alleviated Adriamycin-induced podocyte autophagy, as demonstrated using Pik3r1 siRNA and an overexpression plasmid for Prkaa1/Prkaa2. Furthermore, MHCD could activate the PI3K/AKT/mTOR signaling pathway while suppressing the AMPK/mTOR signaling pathway.

CONCLUSIONS:

This study demonstrated that MHCD can activate the interaction between the PI3K/AKT/mTOR and the AMPK/mTOR signaling pathways to maintain autophagy balance, inhibit excessive autophagy, and play a role in protecting the kidneys and podocytes.

01 May 2024·Pflugers Archiv : European journal of physiology

Renal and cardiac effects of the PDE9 inhibitor BAY 73–6691 in 5/6 nephrectomized rats

Article

Author: Hasan, Ahmed A ; Cao, Yaochen ; Delić, Denis ; Shen, Linghong ; Zhang, Zeyu ; He, Ben ; Krämer, Bernhard K ; Gaballa, Mohamed M S ; Hocher, Berthold ; Yin, Lianghong ; Shi, Xin ; Klein, Thomas ; Chen, Xin ; Wu, Hongwei

It has been suggested that the novel selective phosphodiesterase 9 (PDE9) inhibitor may improve cardiac and renal function by blocking 3',5'-cyclic guanosine monophosphate (cGMP) degradation. 5/6 nephrectomized (5/6Nx) rats were used to investigate the effects of the PDE9 inhibitor (BAY 73-6691) on the heart and kidney. Two doses of BAY 73-6691 (1 mg/kg/day and 5 mg/kg/day) were given for 95 days. The 5/6Nx rats developed albuminuria, a decrease in serum creatinine clearance (Ccr), and elevated serum troponin T levels. Echocardiographic data showed that 5/6 nephrectomy resulted in increased fractional shortening (FS), stroke volume (SV), and left ventricular ejection fraction (EF). However, 95 days of PDE9 inhibitor treatment did not improve any cardiac and renal functional parameter. Histopathologically, 5/6 nephrectomy resulted in severe kidney and heart damage, such as renal interstitial fibrosis, glomerulosclerosis, and enlarged cardiomyocytes. Telmisartan attenuated renal interstitial fibrosis and glomerulosclerosis as well as improved cardiomyocyte size. However, except for cardiomyocyte size and renal perivascular fibrosis, BAY 73-6691 had no effect on other cardiac and renal histologic parameters. Pathway enrichment analysis using RNA sequencing data of kidney and heart tissue identified chronic kidney disease pathways, such as phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) signaling pathway, complement and coagulation cascades, and nuclear factor kappa B (NF-κB) signaling pathway. PDE9i did not affect any of these disease-related pathways. Two dosages of the PDE9 inhibitor BAY 73-6691 known to be effective in other rat models have only limited cardio-renal protective effects in 5/6 nephrectomized rats.

News (Medical) associated with Telmisartan

31 Jan 2024

·www.globenewswire.com

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 201980043698.6 for its antifibrotic drug candidate NP-251 (Repirinast). The invention claims the administration of Repirinast, either alone or in combination with telmisartan, for use in the prophylaxis or treatment of renal fibrosis or kidney disease. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions, which may provide additional protection. The Company was recently issued patents for Repirinast in chronic kidney disease (CKD) from Japan and has also filed corresponding patent applications in Canada, Europe and the United States. Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a unilateral ureteral obstruction (UUO) mouse model. Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing and formulations, and for new composition of matter patents based on novel salt forms. “We are once again pleased to receive another notice of intent to grant a patent from the Chinese Patent Office,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “This will be the second patent granted to the Company in China, and it complements multiple other patents issued in other major world markets as part of our comprehensive global intellectual property strategy.” The Company also announces a grant of 1,625,000 restricted share units pursuant to its RSU Plan (each, an "RSU") to executives and directors, of the Company. Each RSU entitles the recipient to receive one common share of the Company or a cash payment equal to the equivalent of one common share of the Company on vesting. The RSUs vest on the date of grant. The Company has also granted 100,000 stock options exercisable at $0.075 for two years from date of grant, to a consultant of the Company. The stock options vest on the date of grant. The RSUs and stock options are subject to approval by regulatory authorities. About Algernon Pharmaceuticals Algernon Pharmaceuticals is a Canadian clinical stage drug development company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals has active research programs for chronic cough, chronic kidney disease and NASH, and is the parent company of a private subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of psychedelic DMT for stroke and traumatic brain injury. CONTACT INFORMATION Christopher J. MoreauCEOAlgernon Pharmaceuticals Inc.604-398-4175 ext 701 info@algernonpharmaceuticals.cominvestors@algernonpharmaceuticals.comwww.algernonpharmaceuticals.com Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Patent Expiration

30 Nov 2023

·www.globenewswire.com

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 112654357 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251 (Repirinast). The invention claims treating lobular inflammation and nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company was recently issued patents for Repirinast in NASH from the U.S. and Japan, and has also filed corresponding patent applications in Canada and Europe. The company previously disclosed that Repirinast, in a widely used STAM™ mouse model of NASH from SMC Laboratories (Japan): Reduced hepatic fibrosis by 57% compared to vehicle (p < 0.0001);Reduced the NAFLD score, a composite histopathological measure of inflammation, steatosis and ballooning, by 31% compared to vehicle (3.125 vs 4.5 points, p = 0.059);In the same model, telmisartan, a positive control and the standard of care for NASH, reduced fibrosis by 27% (p = 0.014) Repirinast is also the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a unilateral ureteral obstruction (UUO) mouse model. Because patients with NAFLD have a two-fold increased risk of CKD, even when controlling for other comorbidities such as obesity, type 2 diabetes mellitus and insulin resistance, Repirinast is a strong candidate for both indications. Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing and formulations, and for new composition of matter patents based on novel salt forms. “We are pleased to receive this notice of intent to grant from the Chinese Patent Office,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “This will be the first patent granted to the Company in China, and it complements multiple other patents issued in other major world markets as part of our comprehensive global intellectual property strategy.” About Algernon Pharmaceuticals Algernon Pharmaceuticals is a Canadian clinical stage drug development company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals has active research programs for chronic cough, chronic kidney disease and NASH, and is the parent company of a private subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of psychedelic DMT for stroke and traumatic brain injury. CONTACT INFORMATION Christopher J. MoreauCEOAlgernon Pharmaceuticals Inc.604.398.4175 ext 701info@algernonpharmaceuticals.cominvestors@algernonpharmaceuticals.comwww.algernonpharmaceuticals.com Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Patent Expiration

08 Nov 2023

·www.biospace.com

Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast

VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for patent application No. 2021-512244 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251 (Repirinast). The invention claims treating nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company was recently issued a patent from the US patent office for Repirinast in NASH and has also filed corresponding patent applications in Canada, Europe, and China. The company previously disclosed that Repirinast, in a widely used STAM™ mouse model of NASH from SMC Laboratories (Japan): Reduced hepatic fibrosis by 57% compared to vehicle (p < 0.0001); Reduced the NAFLD score, a composite histopathological measure of inflammation, steatosis and ballooning, by 31% compared to vehicle (3.125 vs 4.5 points, p = 0.059); In the same model, telmisartan, a positive control and the standard of care for NASH, reduced fibrosis by 27% (p = 0.014) Repirinast is also the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a unilateral ureteral obstruction (UUO) mouse model. Because patients with NAFLD have a two-fold increased risk of CKD, even when controlling for other comorbidities such as obesity, type 2 diabetes mellitus and insulin resistance, Repirinast is a strong candidate for both indications. Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing and formulations, and for new composition of matter patents based on novel salt forms. “This is another major milestone for Algernon’s innovative drug repurposing program and is further validation of our intellectual property strategy,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. About Algernon Pharmaceuticals Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals has active research programs for IPF with chronic cough, and chronic kidney disease, and is the parent company of a newly created private subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of psychedelic DMT for stroke and traumatic brain injury. CONTACT INFORMATION Christopher J. Moreau CEO Algernon Pharmaceuticals Inc. 604.398.4175 ext 701 info@algernonpharmaceuticals.com investors@algernonpharmaceuticals.com . Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Patent Expiration

100 Deals associated with Telmisartan

External Link

KEGG	Wiki	ATC	Drug Bank
D00627	Telmisartan	C09CA07	DB00966

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	EU	Actavis Group PTC ehf	29 Sep 2010
Cardiovascular Diseases	IS	Actavis Group PTC ehf	29 Sep 2010
Cardiovascular Diseases	LI	Actavis Group PTC ehf	29 Sep 2010
Cardiovascular Diseases	NO	Actavis Group PTC ehf	29 Sep 2010
Essential Hypertension	EU	Boehringer Ingelheim International GmbH	16 Dec 1998
Essential Hypertension	IS	Boehringer Ingelheim International GmbH	16 Dec 1998
Essential Hypertension	LI	Boehringer Ingelheim International GmbH	16 Dec 1998
Essential Hypertension	NO	Boehringer Ingelheim International GmbH	16 Dec 1998
Hypertension	US	Boehringer Ingelheim GmbH	10 Nov 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypercholesterolemia	Phase 3	CZ	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	FR	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	DE	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	HK	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	NL	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	RU	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	SK	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	ZA	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	KR	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	SE	Boehringer Ingelheim GmbH	01 Apr 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02471833 (CTgov)	Phase 1/2	Alzheimer Disease	61	Telmisartan 20mg (Telmisartan 20mg)	ocpkltobkb(cqnuxhanjj) = dxvqsjfhef vkbkszerdu (vljyitrhoj, kbjqflwofy - ofwldoobpw) View more	-	23 May 2024
				Telmisartan 40mg (Telmisartan 40mg)	ocpkltobkb(cqnuxhanjj) = sifrijntij vkbkszerdu (vljyitrhoj, zukamjkqib - ujpwmpodqv) View more
NCT02338232 (CTgov)	Not Applicable	Acute Graft Versus Host Disease	32	Telmisartan	sqdtweojng(lmxdlhnqmn) = hyurknhfmm tybtsusrth (ljplxwiwfe, adxylwrxgy - jplsytnqox) View more	-	01 May 2024
NCT04360551 (CTgov)	Phase 2	Complication \| COVID-19	24	Telmisartan 40mg (Telmisartan)	urwyzoofar(jfjzzwqwem) = qtezsddnap ovkdkrajsn (dfticnoyof, spdskszxpt - jpogijibwu) View more	-	21 Aug 2023
				Placebo (Placebo)	urwyzoofar(jfjzzwqwem) = fnctkctrei ovkdkrajsn (dfticnoyof, nxubmcbqmi - rcszcwkcap) View more
TRIUMF trial (ESC2023)	Not Applicable	Heart failure with reduced ejection fraction	107	Telmisartan	ltngexfnkz(jggfoazfvl) = fsycodcgzv kigfnymbre (gripmxmdvc ) View more	-	20 May 2023
				Enalapril	ltngexfnkz(jggfoazfvl) = plozuprjdl kigfnymbre (gripmxmdvc ) View more
NCT02593110 (CTgov)	Not Applicable	Peripheral Arterial Disease	114	Supervised Treadmill Exercise Therapy+Telmisartan (Telmisartan + Supervised Treadmill Exercise Therapy)	tfnaopboya(qvfldvlbpi) = bqknqvhbru aisssvswlo (mzprhmaxdv, zjoejginha - tcnuekdylg) View more	-	11 Jan 2023
				"No exercise" control group+Telmisartan (Telmisartan + "No Exercise" Control Group)	tfnaopboya(qvfldvlbpi) = cbyzeizpju aisssvswlo (mzprhmaxdv, ohcmctxgpr - ssegdqauxm) View more
NCT02593110 (Pubmed)	Not Applicable	Peripheral Arterial Disease	114	Telmisartan plus exercise	vqmithatfa(lzwlfgzrnm) = loryyldmky kdiskpfyvk (wqerjktqok )	Negative	04 Oct 2022
				Placebo plus exercise	vqmithatfa(lzwlfgzrnm) = cwqumzvdxv kdiskpfyvk (wqerjktqok )
ESC2022	Not Applicable	Prediabetic State	51	telmisartan/amlodipine 80/5mg	ciycngkbwp(refqvlwurv) = xbrvdgesix ijessufczq (hbjujjjjhm ) View more	-	07 Apr 2022
NCT03868839 (CTgov)	Phase 2	Schizoaffective disorder \| Schizophrenia, Treatment-Resistant	6	Telmisartan Pill	wkaxqvfaee(vhfvgzhvtv) = kspwjxcrrc wdyofxlfsv (ljwwrmyrsk, onbydhqbty - qfkdrirlpg) View more	-	02 Mar 2022
CTRI/2016/11/007491 (Pubmed \| Adv Ther)	Phase 3	Coronary Artery Disease \| Essential Hypertension	254	FDC1 (metoprolol 25 mg, telmisartan 40 mg, chlorthalidone 12.5 mg)	fqcecympbc(qzjtswxapw) = lcsnminsdb nnrtjjukjl (btpbabixml ) View more	-	17 Dec 2021
				FDC2 (metoprolol 50 mg, telmisartan 40 mg, chlorthalidone 12.5 mg)	fqcecympbc(qzjtswxapw) = yjkoxlxxel nnrtjjukjl (btpbabixml ) View more
NCT04355936 (Pubmed)	Phase 4	COVID-19	162	Telmisartan (Standard care)	gqzxcirnws(hxktsxzolt) = jvnaxmrkso flqoeaiiup (nxygumyotl ) View more	Positive	01 Jul 2021
				Telmisartan 80 mg	gqzxcirnws(hxktsxzolt) = vymqaqdpnp flqoeaiiup (nxygumyotl ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis